scholarly journals MiR-539-5p negatively regulates migration of rMSCs induced by Bushen Huoxue decoction through targeting Wnt5a

2019 ◽  
Vol 16 (7) ◽  
pp. 998-1006 ◽  
Author(s):  
Liuchao Hu ◽  
Yamei Liu ◽  
Bin Wang ◽  
Zhifang Wu ◽  
Yingxiong Chen ◽  
...  
2014 ◽  
Vol 10 (3) ◽  
pp. 1635-1641 ◽  
Author(s):  
SHUIFEN YE ◽  
YONG GU ◽  
YIHUI XU ◽  
WEN FAN ◽  
XIAOTING WANG ◽  
...  

2021 ◽  
Vol 10 (3) ◽  
pp. 49-49
Author(s):  
Shuai-Hua Feng ◽  
Fang Xie ◽  
Hong-Yan Yao ◽  
Guan-Bao Wu ◽  
Xiang-Yun Sun ◽  
...  

2021 ◽  
Vol 2021 ◽  
pp. 1-14
Author(s):  
Lan-Chun Liu ◽  
Qi-Yuan Mao ◽  
Chao Liu ◽  
Jun Hu ◽  
Lian Duan ◽  
...  

Objective. The aim of this meta-analysis was to systematically evaluate the effectiveness and safety of the traditional Chinese medicine (TCM) formula Bushen Huoxue Decoction (BSHXD) in treating coronary heart disease (CHD). Methods. Randomized controlled trials (RCTS) of BSHXD in treating CHD were searched until March 2020, through six electronic databases: PubMed, Cochrane Library, CNKI, WanFang, SinoMed, and VIP. This study used the Cochrane Risk Test bias tool in the Cochrane Handbook to assess the quality of the methodology. Review Manager (RevMan) 5.3 was used to analyze the results. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria were applied in the classification of evidence quality. Results. Ten RCTs involving 901 patients were finally included in this meta-analysis. It revealed that the effectiveness of BSHXD in treating CHD was significantly better than that of the conventional western medicine (CWM) treatment ( P < 0.00001 ). The effective rate of BSHXD treatment group on ECG was also significantly higher than that of CWM group ( P < 0.00001 ). The low-density lipoprotein cholesterol was decreased in the treatment groups compared with those in the control groups ( P < 0.00001 ). There was also a reduction in frequency and duration of angina pectoris ( P < 0.00001 ). There were no significant differences in TC level ( P = 0.08 ), TG level ( P = 0.86 ), and HDL level ( P = 0.76 ) between the treatment and control groups. Five studies had informed adverse events, including nausea and diarrhea. Conclusion. Our findings laid the foundation to the use of TCM Formula BSHXD in combination with conventional western medicine for treating CHD. However, due to the limitation of the quality of the included researches, in addition to potential reporting bias, the above conclusions still need verification by higher-quality and better-designed studies.


2014 ◽  
Vol 6 (6) ◽  
pp. 720
Author(s):  
Zi-Yan Wang ◽  
Mei Zhang ◽  
Chun-Qin Li ◽  
Shi-Jiao Wu ◽  
Xue-Jun Xie

2020 ◽  
Vol 2020 ◽  
pp. 1-11
Author(s):  
Xiaoling Feng ◽  
Sha Jiang ◽  
WingTing Leung ◽  
Ling Wang ◽  
Hans Jürgen Gober ◽  
...  

BuShen HuoXue decoction (BSHXD) has been used to treat patients with unexplained recurrent spontaneous abortion (URSA). However, the chemical compounds and mechanism by which BSHXD exerts its therapeutic and systemic effects to promote the proliferation of decidual stromal cells (DSCs) has not been elucidated. This work sought to elucidate the cellular and molecular mechanism of BSHXD in terms of inflammatory factors IL-17A in DSCs in vitro because of the critical roles of inflammation, apoptosis, and immunity in the development and progression of pregnancy loss. Twelve migratory chemical compounds from BSHXD extract were qualitatively analyzed by high-performance liquid chromatography (HPLC). DSCs were collected from normal early pregnancy (NEP) and URSA to determine whether BSHXD affects IL-17A/IL17RA via the PI3K/AKT pathway. Abnormal apoptosis and activated p-AKT were observed in URSA DSCs. RhIL-17 A, LY294002 (a PI3K pathway inhibitor), and BSHXD were individually or simultaneously administered in NEP DSCs, suggesting that BSHXD restored cell proliferation without excessive stimulation and IL-17A promotes proliferation via the PI3K/AKT pathway. Using the same intervention in URSA DSCs, qRT-PCR measured the upregulated mRNA levels of IL-17 A/IL-17RA, PI3K, AKT, p-AKT, PTEN, Bcl-2, and Bcl-xL and downregulated mRNA levels of BAD and ACT1 after treatment with BSHXD. We demonstrated that BSHXD affected IL-17A/IL-17R via PI3K/AKT pathway to promote the proliferative activity of DSCs in URSA. These results provide a new insight to further clarify the relationship between inflammation and apoptosis and the mechanism of imbalance in the dynamic equilibrium between Th17/Treg immune cells at the maternal-fetal interface.


Sign in / Sign up

Export Citation Format

Share Document